Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin

Completed

Conditions studied: Urinary Tract Infection, Fluoroquinolone, Bacteremia

In brief

The information collected will optimize the management of patients with urinary tract infections with secondary bacteremia, primarily with gram negative bacteria especially Escherichia coli. The current IDSA guideline endorses the use of fluoroquinolones and trimethoprim-sulfamethoxazole as the first line agents. However, over use of this empiric regimen could result in in appropriate treatment of bacteremia.

Key facts

Study ID

NCT00414362

Run by

University of Pittsburgh

People needed

1000

Starts

2007-02-01

Expected to finish

2017-06-01

Last updated by the study team

2018-06-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical information is collected by chart review of "case" and "control" patients. A "case" patient is defined as follows:
• One or more blood cultures are positive for Gram-negative bacteria.
• The same organism is recovered in urine culture within a 48-hour period.
• The organism is ciprofloxacin resistant.
• A "control" patient is defined as follows:
• One or more blood cultures are positive for Gram-negative bacteria.
• The same organism is recovered in urine culture within a 48-hour period.
• The organism is ciprofloxacin susceptible.

You may not qualify if…

• negative culture

Where it is running

• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.